NIH Director Monica Bertagnolli will resign on Jan. 17, she told staff this week, ending her tenure as the head of the $48 billion biomedical research agency after only a year. The NIH has typically been an agency with bipartisan support. But lingering Republican anger over the handling of the COVID-19 pandemic has pushed NIH squarely into partisan crosshairs.
Artificial intelligence models are ever-hungry black boxes that need boatloads of bits and bytes from a wide stream of real-world data in order to produce insights about patients and their care. To satisfy this need, a trove of companies have popped up to buy patient data from hospitals and sell it to those wanting to train AI or do research.
“The current system leads people to avoid primary care, which is the worst possible outcome,” Boyarsky Pratt says, later adding, “Research shows our current approach is making obesity worse. It feels like my calling to create something that welcomes patients.”
Advocates say interstate compacts, which allow professionals to use their work licenses in multiple states, can solve Texas’ workforce shortage. Skeptics fear Texas would send more workers than it would receive.
A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday. The U.S. Court of Appeals for the District of Columbia Circuit halted the launch, which could have begun as early as Thursday, while it considers Novartis' emergency request for a longer pause. A separate ruling on Wednesday from U.S. District Judge Dabney Friedrich in Washington had cleared a hurdle for MSN to introduce the first U.S. generic of Switzerland-based Novartis' best-selling drug, which brought the company more than $6 billion in revenue in 2023.